Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
Le Lézard

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...